A mutation in the Kirsten rat sarcoma virus transforming protein (KRAS) is the most common genomic driver identified in patients with lung adenocarcinoma. It is a key component of the PI3K and MAPK pathways and is an important regulator of cell proliferation and survival. Tobacco use and ...
KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer medicine. 2016; 5:256-264.Ghidini M, Personeni N, Bozzarelli S, et al. KRAS mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Med 2016;5:256-64....
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531-542. 6. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harbori...
2025年2月13日,武汉大学中南医院医学研究院/生命科学学院钟波教授与武汉大学人民医院林丹丹教授课题组合作在Dev Cell上发表了题为KRAS4B oncogenic mutants promote non-small cell lung cancer progression via the interaction of deubiqui...
In addition, patients with KRAS mutations usually have a poor response to current standard therapy11. There has been an urgent and unmet need to target KRAS mutations in KRAS-driven cancer. Recently, there has been light on the horizon for one specific mutation, KRAS (G12C). With the ...
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that ...
Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high tri
[1]Jänne PA, Riely G, Gadgee SM等人。‘Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation’,《N Engl J Med》；2022;386:22. doi:10.1056/NEJMoa2204619.[2]Gadgeel SM, Jänne PA, Spira AI等人。‘KRYSTAL-1: two-year follow-up of adagrasib (MRTX849) ...
[6]Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation [J]. N Engl J Med, 2021, 384(25):2371-2381. [7]NCCN clinical practice guidelines in oncology: non-small cell lung cancer, version 5. 2021....
[5]https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [6]https://www.novartis.com/news/media-releases/novartis-announces-early-clinical-data-unique-krasg12c-inhibitor-american-association-cancer-research-annua...